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ABSTRACT
TARGETING THE MAJOR REGULATOR OF MITOSIS
J. Mason Hoffman
July 27, 2017
Mitosis-inhibiting chemotherapeutics (e.g. taxanes) are frequently used to
treat multiple cancer types. Recently, there has been much concern about the
limited success of these drugs due to resistance and a lack of molecular targets.
Thus, there is high demand for new drugs with diverse cellular targets. Targeting
the regulators of mitosis is a promising approach. The anaphase promoting
complex/cyclosome (APC/C) is an E3 ubiquitin ligase that controls cell cycle
progression at multiple points. The interaction of ANAPC2 and ANAPC11,
catalytic core subunits, is necessary for APC/C function. An in silico approach
was used to identify compounds predicted to prevent assembly of ANAPC2 and
ANAPC11, causing APC/C inhibition and mitotic arrest. Several of the predicted
compounds possess cytotoxic properties in multiple cancer cell types. These hit
compounds induce mitotic arrest and cell death in malignant, but not nonmalignant cells. Additionally, hit compounds are effective in taxane-resistant
cells.
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INTRODUCTION
Mitosis-inhibiting chemotherapeutics (e.g. taxanes) are frequently used in
combination chemotherapy to treat multiple types of cancer. These are effective
because they exploit the mitotic spindle assembly checkpoint (SAC), causing
inhibition of the anaphase promoting complex/cyclosome (APC/C), mitotic arrest,
and apoptosis. Successful therapy is often hindered by drug-resistant tumors,
neurotoxicity, and limited supply. All current mitotic inhibitors, and the majority
that are in development, target a single protein: tubulin. Therefore, mutations in
tubulin or SAC proteins create cancer cells that are resistant to all current mitotic
inhibitors. Thus, there is high demand for new drugs with diverse cellular targets.
Rather than targeting tubulin, a promising alternative approach is targeting the
proteins that regulate mitosis. The APC/C is an E3 ubiquitin ligase that is vital for
progression through mitosis and G1-phase. The APC/C ubiquitinylates its protein
targets, which marks them for degradation. Many target proteins of the APC/C
have well characterized proliferative or anti-proliferative roles. By carefully
orchestrating the degradation of these proteins, the APC/C facilitates the orderly
progression of the cell cycle and timing of critical cellular events.
The Ubiquitin-Proteasome System and the Cell Cycle
The cell cycle is a highly regulated unidirectional sequence of events in
which a cell replicates its genetic material and divides into two daughter cells. A
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complex network of proteins is required to coordinate progression through each
phase of this process. In eukaryotic cells, the cell cycle is divided into four
phases: G1 (gap 1), S (Synthesis, DNA replication), G2 (gap 2), and M (Mitosis,
division of cellular components to two daughter cells).
Of particular importance in controlling phase transitions are a family of
protein kinases, known as cyclin-dependent kinases (CDKs). CDKs are
constitutively-expressed and regulate the activity of their targets by
phosphorylation. As their name suggests, they are only active when associated
with positive regulatory subunits, known as cyclins [1]. The prototypical cyclins
involved in cell cycle control are cyclins A, B, D, and E, each of which associates
with different CDKs. Expression of cyclins, unlike CDKs, oscillates during each
cell cycle resulting in activation of different CDKs at unique times. Thus, through
their control of CDK activity, cyclins are key to promoting cell cycle progression.
This pattern of CDK activation allows phosphorylation of key targets involved in
DNA replication and mitosis at the appropriate times. Further complicating
matters, CDK activity is negatively regulated by post-translational modifications
(PTMs, e.g. phosphorylation) and the periodic expression of CDK inhibitors
(CDKNs) [2]. A delicate balance between synthesis and degradation of cyclins,
CDKNs, and other regulatory proteins is required for cell cycle control [1, 3].
Perhaps the most important means of CDK regulation is the periodic
degradation of cyclins and CDKNs by ubiquitin-mediated proteolysis [4, 5].
Ubiquitin is a small, highly-conserved protein that is covalently attached to a
target protein through a process called ubiquitinylation. It is the slowest evolving
2

protein yet identified, highlighting the conserved importance of its function.
Ubiquitinylation, like other PTMs, can alter the stability, structure, localization and
function of target proteins [6, 7]. More specifically, ubiquitinylation is the
formation of an isopeptide bond between the C-terminus of ubiquitin and a lysine
within a confined domain of the target. Polyubiquitinylation is a modification
which contains chains of multiple linked ubiquitins [6, 8, 9]. In terms of cell cycle
control, the predominant function of polyubiquitinylation is to mark target proteins,
such as cyclins, CDKNs, and other key regulatory proteins, for degradation [10].
While polyubiquitination can have numerous cellular effects, one of the
most studied roles of polyubiquitination is in protein degradation. Other functions
of ubiquitinylation include enzyme activation, epigenetic modification, receptor
internalization, apoptosis, polycomb silencing, and signaling pathways such as
tumor necrosis factor, interleukin 1 beta, CD40 ligand, Toll-like receptors, and
Nucleotide-binding oligomerization domain-containing protein 2 [11-15]. As would
be expected of a system that regulates so many important cellular processes,
there is a large and growing list of proteins involved in this process of
ubiquitinylation and degradation of target proteins. These proteins comprise what
is known as the ubiquitin-proteasome system (UPS). This system of selective,
programmed protein degradation ensures the unidirectionality of the cell cycle
and the appropriate timing of cell cycle events [5, 10, 16].
The ubiquitin-proteasome system facilitates the degradation of target
proteins by directing them to the 26S proteasome, a large multi-subunit complex
consisting of multiple proteases [17, 18]. The core of the proteasome, termed the
3

20S proteasome, contains chymotrypsin-like, trypsin-like, and caspase-like
enzymatic activities [17]. The 26S proteasome is formed by association of two
19S caps with opposite ends of the 20S core [7]. These caps act as regulatory
subunits for recognition of ubiquitinylated proteins. Upon recognition, the protein
is unfolded in an ATP-dependent manner by the 19S subunits and introduced
into the inner chamber of the 20S subunit for degradation. While rare cases of
ubiquitin-independent proteasomal degradation have been documented, most
cases rely on signaling via protein ubiquitinylation [17].
Ubiquitinylation of a target protein is facilitated by a 3-step cascade of
enzymatic reactions (Figure 1) [7]. The initial step requires a ubiquitin-activating
enzyme (E1), which binds to the C-terminal glycine of ubiquitin via an ATPdependent reaction [19]. Following activation, ubiquitin is transferred from the E1
to a ubiquitin-conjugating enzyme (E2), and finally, an E3 ubiquitin ligase
transfers ubiquitin from the E2 to the target protein [20]. Multiple rounds of
ubiquitinylation occur, allowing the target protein to be recognized and degraded
by the 26S proteasome (Figure 1). E3 ubiquitin ligases provide the UPS with a
high degree of specificity, which is required for this system to target the correct
proteins at the appropriate times [6, 7].
E3 ubiquitin ligases, enzymes responsible for the transfer of ubiquitin from
an E2 ubiquitin-conjugating enzyme to the target protein, are the largest and
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Figure 1. Outline of protein degradation by the ubiquitin proteasome
system. E1 ubiquitin-activating enzymes first covalently attach to ubiquitin via an
ATP-dependent reaction. Ubiquitin is then transferred to an E2 ubiquitinconjugating enzyme. An E3 ubiquitin ligase binds its substrate protein and the
ubiquitin-bound E2 enzyme and catalyzes the covalent attachment of ubiquitin to
the substrate. Multiple rounds of substrate ubiquitinylation lead to the formation
of a polyubiquitin chain. The polyubiquitinylated substrate is subsequently
recognized and degraded by the 26S proteasome. The E3 ubiquitin ligase is now
free to repeat the cycle from the beginning. The four main classes of E3 ubiquitin
ligases (HECT, PHD-finger, RING-finger, and U-box types) and the members of
the RING-finger E3 subfamily (APC/C, SCF, ECV, CUL3-based, CUL4-based,
ECS, CUL7-based, and PARC E3s) are listed. The two RING-finger E3s in bold,
the APC/C and SCF, are both critical for cell cycle regulation.
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most complex members of the E1-E2-E3 cascade [21]. While humans possess
only 8 E1 ubiquitin-activating enzymes and 38 E2 ubiquitin-conjugating enzymes,
there are more than 600 human E3 ubiquitin ligases [19, 20]. There are four
classes of E3 ubiquitin ligases: HECT (homologous to E6-AP C-terminus)
domain-containingE3s, U-box domain-containing E3s, PHD (plant homeodomain)
finger domain-containing E3s, and RING (really interesting new gene) fingercontaining E3s (Figure 1) [21].
The RING finger E3s are the largest E3 class and are further divided into
subclasses (Figure 1). One of these is the cullin-RING ligase (CRL) subclass,
which includes two structurally similar protein complexes that are vital to cell
cycle regulation: The SKP/cullin/F-box-containing (SCF) complexes and the
anaphase promoting complex/cyclosome (APC/C) (Figure 1) [21]. The catalytic
cores of these CRLs are highly similar, consisting of a cullin-like protein and a
Zn-RING-finger protein [21, 22]. Cullin and Zn-RING-finger proteins are essential
for catalyzing the transfer of ubiquitin to the target protein [23]. Additionally, these
E3 ubiquitin ligases associate with specific coactivator subunits, which determine
substrate specificity [24-26].
E3 ubiquitin ligases, like CDKs, are subject to multiple layers of regulation,
including activating and inhibitory PTMs, association with coactivators and
inhibitors, and periodic expression of various subunits [24-30]. Additionally,
deubiquitinating enzymes (DUBs), proteases that cleave ubiquitin from modified
proteins, directly counteract E3 ubiquitin ligases. In humans, over 100 DUBs
have been identified, each targeting specific subsets of proteins. DUBs have
6

demonstrated roles in many cellular processes, including DNA repair, chromatin
remodeling, various signaling pathways, and cell cycle regulation [31]. A study by
Huang et. al provided an example of the importance of DUBs in cell cycle
regulation [32]. Briefly, they showed that ubiquitin carboxyl-terminal hydrolase 37
(USP37), a DUB that both antagonizes and is a substrate of the APC/C, is
important for regulation of S-phase entry [32]. USP37 is fully activated at G1/S by
phosphorylation by CDK2/cyclin E or CDK2/cyclin A, allowing it to stabilize cyclin
A by deubiquitylation, promoting entry into S-phase. In mitosis, CDK2 inactivation
leads to loss of USP37 activity and its degradation as an APC/C substrate. This
prevents USP37 from antagonizing the APC/C, allowing timely degradation of
key APC/C mitotic substrates, and promoting mitotic progression. Several other
examples of DUBs in cell cycle regulation are detailed by Wei et. al [31].
The remainder of this section will focus on the role of CRLs in cell cycle
regulation, control of CRL activity, and particularly, the APC/C in regulation of
mitosis.
Two Cullin-RING Ligases Control Cell Cycle Progression
SCF E3 Ubiquitin Ligases are critical components of cell cycle regulation.
They are particularly important for regulating entry into S-phase, as well as
mitotic entry [29, 33]. There are three core components of SCF ligases which are
invariable: SKP1 (S-phase kinase-associated protein 1), CUL1 (Cullin-1), and
RBX1 (RING-box protein 1) [34]. SCF ligases are the largest class of E3 ligases
and are responsible for the degradation of an estimated 20% of ubiquitin-
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proteasome-regulated proteins, including many cell cycle regulatory proteins
(Table 1) [6, 7, 35-37].
SCF complexes are classified as CUL1-containing E3 ubiquitin ligases.
CUL1 is a cullin protein that functions as a scaffold protein. In addition to CUL1,
SCF ubiquitin ligases contain RBX1, a RING-finger protein, and SKP1, an
adaptor protein that binds F-box proteins [37]. There are at least 69 human F-box
proteins, each with a conserved C-terminal F-box motif for binding SKP1. F-box
proteins function as the SCF substrate determining subunit and are divided into
three subfamilies based on their C-terminal substrate binding domains: the
FBXW (WD40 substrate binding domains), FBXL (leucine-rich repeats (LRR)
substrate binding domains), and FBXO (contains other binding domains such as
kelch repeats or proline-rich repeats) subfamilies [37-39]. Each F-box protein
recognizes a different set of substrates depending on which substrate binding
domains they contain. Interestingly, there is an overlap in substrate recognition,
allowing one substrate to be targeted by multiple F-box proteins. Because all
three subfamilies of F-box proteins are implicated in cell cycle control, these SCF
complexes are likely to be ineffective as a chemotherapeutic target due to the
redundancy of F-box substrate-targeting.
SCF E3s containing FBXW1 (SCF(FBXW1)), also known as βTrCP (beta-transducin repeat containing protein), have been well documented for
their role in cell cycle control. FBXW1 is highly homologous to APC/C substrate
specificity subunits, CDC20 (cell division cycle 20) and CDH1 (CDC20 homolog
1) [40], which will be discussed in the following paragraphs. SCF(FBXW1)
8

complexes have been implicated in the targeting of numerous cell cycle
regulators including EMI1/FBXO5 (early mitotic inhibitor 1/ F-box only protein 5),
WEE1 (Wee1-like protein kinase), CDC25A (cell division cycle 25A), Cyclin D1,
PLK4 (polo-like kinase 4), BORA (protein aurora borealis), and Securin (Table 1)
[37]. EMI1 is an inhibitor of the APC/C in S and G2 phase. In prophase,
degradation of EMI1 mediated by SCF(FBXW1) is required for activation of the
APC/C and mitotic progression [41]. This is one of many examples of the
complex co-regulatory network between SCF complexes and the APC/C [4, 26,
42]. Similarly, FBXW1-dependent degradation of WEE1 kinase, a negative
regulator of mitotic entry, is required for cells to transition from G2 to M [43].
Another SCF(FBXW1) target, PLK4, is a serine/threonine protein kinase critical
for centriole duplication [44]. SCF(FBXW1) has been found to target PLK4 for
degradation, which prevents centriole amplification and chromosomal instability
[45, 46]. Securin is an inhibitor of the metaphase to anaphase transition in
mitosis, and is well-documented as a mitotic substrate of the APC/C [40, 47-53].
However, in response to UV irradiation, securin degradation was found to be
mediated by SCF(FBXW1), resulting in cell cycle arrest [54, 55]. CDC25A
degradation is required for entry into S-phase. In response to DNA damage,
CDC25A is phosphorylated, allowing its recognition by SCF(FBXW1), leading to
delayed S-phase entry [56, 57]. Another member of the FBXW F-box protein
subfamily, FBXW7, targets several key cell cycle regulators. Cyclin E, an
activator of CDK2, promotes the G1/S-phase transition and its phosphorylated
form is ubiquitinated by SCF(FBXW7) [21, 58].

9

Table 1 Reported substrates of each F-box subfamily.

F-box subfamily

Target proteins

FBXW

FBXL

FBXO

EMI1/FBXO5

CDKN1A

Cyclin B

WEE1

CDKN1B

Cyclin D1

CDC25A

CDKN1C

TP53

CDC25B

Cyclin E

CHK1

Cyclin D1

Cyclin A

CDT1

Cyclin E

CDH1

CDT2

PLK4

Cyclin D2

MDM2

Bora

Cyclin D3

BRCA1

Securin

Aurora A

Aurora A
Aurora B
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Aurora kinases A and B are important regulators of mitosis that ensure proper
segregation of chromosomes, and both have been identified as SCF(FBXW7)
targets [59-62].
FBXL proteins, a 22-member F-box subfamily, are equally important as
the FBXW subfamily. Targets of these FBXL proteins include multiple CDKNs,
cyclins, and various cell cycle kinases (Table 1) [21, 37]. The most studied
member of this subfamily is FBXL1, also called Skp2. Degradation of CDKN1B
(Cyclin-dependent Kinase Inhibitor 1B, p27Kip1) is reportedly mediated by FBXL1,
a step required for S-phase entry, [63, 64]. Other negative regulators of the cell
cycle, such as the CDK inhibitors CDKN1A (Cyclin-dependent Kinase Inhibitor
1A, p21CIP1) and CDKN1C (Cyclin-dependent Kinase Inhibitor 1C, p57 Kip2), have
been documented as FBXL1 targets [65, 66]. Degradation of these proteins
promotes cell cycle progression in S and G2 phases. Numerous other targets of
FBXL-containing SCF complexes have been reported and are reviewed by
Nakayama et.al [67] and Zheng et. al [37]. Like the SCF(FBXW) complexes, the
SCF(FBXL) complexes are intertwined in a complex regulatory network with the
APC/C. For example, degradation of FBXL1 is mediated by the APC/C in G1phase [29]. Therefore, SCF(FBXL1) becomes inactivated and is only reactivated
when APC/C activity decreases and FBXL1 is stabilized.
The third subfamily of F-box proteins is FBXO, or F-box only. Unlike
FBXW proteins, which contain only C-terminal WD40 (structural motif terminating
in W-D dipeptide) motifs, and FBXL proteins, which contain only C-terminal LRR
(leucine-rich repeat) motifs, FBXO proteins can possess any of 21 other
11

homology domains for substrate recognition. There are at least 36 FBXO
proteins, many of which are not well understood. However, what is known about
FBXO proteins demonstrates their importance in cell cycle regulation (Table 1)
[37]. FBXO1, or Cyclin F, contains an amino acid sequence similar to that of
Cyclin A and its protein levels oscillate throughout the cell cycle, increasing in S,
peaking in G2, and disappearing in mitosis [68, 69]. FBXO1 has been reported to
bind Cyclin B and facilitate its nuclear import, implicating it in regulation of mitotic
entry [70]. The relationship between SCF complexes and the APC/C is further
complicated by the fact that FBXO5 (also called EMI1, see above) is an APC/C
inhibitor and is itself targeted for degradation by a separate SCF complex
containing FBXW1 [37, 41]. FBXO5, through regulation of APC/C activity, helps
to control mitosis by regulating levels of Cyclin A, Cyclin B, securin, and other
mitotic targets of the APC/C. Other notable targets of FBXO proteins include
TP53, MDM2 (mouse double minute 2), BRCA1 (breast cancer type 1
susceptibility protein), Cyclin D, CHK1 (checkpoint kinase-1), and CDT1
(chromatin licensing and DNA replication factor 1) [37].
The APC/C controls the cell cycle in mitosis and G1-phase and is the
counterpart to SCF complexes, which are largely responsible for regulation of Sand G2-phase progression. The APC/C is a large multi-subunit E3 ubiquitin
ligase that is essential for proliferation and is the master regulator of mitosis [4,
24, 48, 52, 53]. It also plays a role in promoting the G1 progression [2, 27, 7174]. An atomic structure of the full complex was determined in 2015, providing
insights into the structural and functional roles of each subunit [75]. The APC/C
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has at least 14 subunits that assemble into a 1.5 MDa complex [40]. Within the
complex, individual subunits may be grouped into 3 sub-complexes: scaffolding,
catalytic and substrate recognition, and tetratricopeptide repeat (TPR) arm subcomplexes [40, 53]. The catalytic sub-complex contains ANAPC10 and, like SCF
complexes, has a cullin-like subunit, ANAPC2, and a RING-finger subunit,
ANAPC11. The scaffolding sub-complex is made up of ANAPC1, ANAPC4, and
ANAPC5. The TPR arm, which provides binding sites for scaffolding subunits
and coactivators, consists of ANAPC3, ANAPC6, and ANAPC8. In contrast to the
approximately 70 F-box proteins that determine substrates for SCF complexes,
APC/C substrate selection is determined primarily by association with one of two
coactivators: CDC20 and CDH1 [25, 76, 77].
In mitosis, numerous steps are required for full APC/C activation including
degradation of inhibitors, association with coactivators, and phosphorylation of
core subunits [4]. In G2 and early mitosis, the APC/C binds CDC20
(APC/C(CDC20)), which functions as its substrate selectivity subunit (Table 2)
[24, 78]. CDC20 contains a WD40 repeat domain, which is responsible for
binding substrate D-box destruction motifs (RXXLXXXXN) [24]. As previously
mentioned, APC/C(CDC20) is inhibited by EMI1 (FBXO5), which prevents
substrate recognition by CDC20 and allows mitotic cyclins to accumulate, driving
CDK1 activity and mitotic progression [37, 41, 79]. EMI1 is subsequently
phosphorylated in early mitosis by CDK1-Cyclin B and polo-like kinases (PLKs)
targeting it for SCF(FBXW1)-mediated ubiquitinylation [80, 81]. Degradation of
EMI1, however, is not sufficient to activate APC/C(CDC20). To activate
13

Table 2. List of reported APC/C(CDC20) and APC/C(CDH1) targets

Coactivator

Target protein

CDC20

CDH1

Cyclin B

Cyclin B

Cyclin A

Cyclin A

Securin

CDC25A

CDKN1B

SKP2

PLK1

UBE2C

Aurora A

FOXM1

Aurora B

Geminin

Anillin

CDH1

Geminin
CDC20
NEK2A
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APC/C(CDC20) fully, the mitotic checkpoint, or spindle-assembly checkpoint
must be satisfied [28, 82, 83]. The SAC functions to prevent unequal segregation
of genetic material between two daughter cells by inhibiting APC/C(CDC20) until
the cell has achieved proper attachment of mitotic spindle microtubules to all
sister chromatids [84, 85]. Briefly, the SAC possesses a sensory mechanism that
detects unattached kinetochores, promoting formation of a multisubunit mitotic
checkpoint complex (MCC) that halts mitotic progression by inhibiting
APC/C(CDC20). The interplay between the SAC and the APC/C is complex will
be described in the following paragraphs. Once the SAC is satisfied, the MCC
disassembles and the APC/C is phosphorylated at no fewer than 34 mitosisspecific sites [86]. Kraft et. al found that of these 34 sites, 15 can be
phosphorylated by CDK1 and 3 by Plk1, but full activation requires
phosphorylation only at CDK1 sites [86]. Fully activated APC/C(CDC20), in a
negative feedback loop, targets Cyclin B for degradation, leading to CDK1
inactivation and promoting mitotic exit [47, 48, 50, 51]. Concurrently,
APC/C(CDC20) also targets securin, an inhibitor of the cysteine protease
separase [49]. APC/C(CDC20)-mediated degradation of securin activates
separase, which then cleaves cohesion subunit RAD21 (double-strand-break
repair protein rad21 homolog), allowing separation of sister chromatids and
promoting anaphase progression [87].
Prior to APC/C activation, CDH1, the second APC/C coactivator, is
maintained in a phosphorylated form by CDK1, preventing its association with the
APC/C. Following APC/C(CDC20)-mediated Cyclin B degradation and CDK1
15

inactivation, CDH1 is dephosphorylated, allowing its association with the APC/C
(APC/C(CDH1)) [27, 88, 89]. CDC20 is a substrate of APC/C(CDH1), and its
degradation allows CDH1 to take over as the substrate specificity subunit (Table
2) [27, 74, 78]. Additionally, as previously mentioned, APC/C(CDC20) relies on
phosphorylation to become active, whereas phosphorylation inhibits binding of
CDH1. The opposite regulation of CDC20 and CDH1 by phosphorylation is a
major factor that allows for the quick exchange of the two coactivators. CDH1,
like CDC20, contains WD40 repeats that recognize substrate D-box destruction
motifs, but it can also recognize KEN-box motifs (KENXXXN) [25]. In late mitosis,
APC/C(CDH1) continues to target Cyclin B degradation, keeping CDK1 activity
low [90]. Many critical regulators of cytokinesis, centrosome replication, and
mitotic spindle movement have been documented as APC/C(CDH1) targets [52].
In anaphase, PLK1 is targeted for destruction by APC/C(CDH1), allowing
dephosphorylation of proteins involved in elongation of the mitotic spindle [91].
During mitotic exit, APC/C(CDH1) substrates include both Aurora A and Aurora B
mitotic kinases, Kinesin-like protein KIFC1 (kinesin family member C1), and the
actin-binding protein anillin [92-96]. By promoting the degradation of these late
mitotic targets, APC/C(CDH1) ensures disassembly of the components of the
kinetochore, mitotic spindle, and the cytokinetic furrow before the next cell cycle
begins [97].
In G1, the APC/C plays a critical role in preventing premature S-phase
entry until pre-replication complexes (pre-RCs) have been assembled at the
replication origins. To this end, CDK activity is kept low by continued
16

APC/C(CDH1)-mediated cyclin degradation. Additionally, APC/C(CDH1) controls
CDK activity by targeting FBXL1 (SKP2), an SCF component with several CDKN
targets [29, 42, 63, 65, 66]. Assembly of the pre-RCs is controlled by
APC/C(CDH1) by targeting geminin, an inhibitor of pre-RC formation, for
degradation [2, 73, 90]. When APC/C(CDH1) is inactivated in late G1, geminin is
stabilized, which ensures against origin re-licensing until the next cell cycle.
The APC/C is highly regulated, both temporally and in terms of substrate
targeting. As has been discussed, this regulation is achieved through its
association with adaptors, like CDC20 and CDH1, binding of APC/C inhibitors,
like EMI1, and phosphorylation of the APC/C core. Additionally, in mitosis, the
APC/C is the target of the SAC [4, 22, 28, 52, 98, 99].
The APC/C and the SAC
Equal division of sister chromatids between two daughter cells is an
inherently dangerous process, as mistakes result in daughter cells with
chromosomal abnormalities, leading to cell death or cancer. For this reason,
mitosis is a highly regulated and complex sequence of events. Mitosis is divided
into four distinct phases: prophase, metaphase, anaphase, and telophase.
During prophase, chromosomes condense, the nuclear envelope
disappears, and the mitotic spindle begins to form (Figure 2). The mitotic spindle
consists of microtubules attached to a microtubule organizing complex called the
centrosome. Each pair of sister chromatids is joined together at the centromere
by a protein complex called the kinetochore. During metaphase, microtubule
spindle fibers originating from the two polar centrosomes will attach to the
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Figure 2. Illustration of the mechanism of the SAC. Unattached kinetochores
activate the SAC and produce an inhibitory signal targeting the APC/C. Proper
kinetochore attachment, in metaphase, inactivates the SAC, relieving inhibition of
the APC/C. Active APC/C promotes the metaphase-anaphase transition.
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kinetochore of each pair of sister chromatids (Figure 2). Microtubule motor
proteins located near each of the centrosomes pull the microtubules in opposite
directions, placing tension on kinetochores. Because the sister chromatids are
still joined at the kinetochore, sister chromatids arrange themselves in the middle
of the cell, forming a line called the metaphase plate. In anaphase, cleavage of
cohesins, proteins that hold sister chromatids together, allows each sister
chromatid to be pulled to opposite ends of the cell by shortening of kinetochoreassociated microtubules (Figure 2). However, before proceeding to anaphase,
the cell must pass the spindle assembly checkpoint (Figure 2). Microtubuletargeting drugs, such as paclitaxel, function by exploiting the SAC. By interfering
with microtubule function, paclitaxel activates the SAC, leading to APC/C
inhibition, mitotic arrest, and apoptosis in cancer cells. In the absence of spindle
disruption, the SAC will be satisfied and the cell will progress through anaphase
to telophase, during which, sister chromatids reach the poles of the cell, nuclear
envelopes begin to form, and spindle microtubules depolymerize. Following
telophase is cytokinesis, where the cytosol and its contents are divided into two
daughter cells, each with a full set of genetic material.
The SAC is a quality control mechanism that prevents unequal
segregation of chromatids between two daughter cells. In metaphase,
chromosomes that are unattached or improperly attached to the mitotic spindle
promote SAC activation and halt cell division until the mistake can be corrected.
Even a single unattached kinetochore is sufficient to activate the SAC and
prevent mitotic exit. One of the first studies to point out this phenomenon was
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performed by Raymond Zirkle, who noted that metaphase cells will “wait” when
just one chromosome was retarded [100]. Later studies using microtubule
depolymerizing agents, such as nocodazole and colchicine, found that the
metaphase-anaphase transition was delayed in response to inhibition of mitotic
spindle assembly [101]. Fittingly, the newly discovered mitotic checkpoint was
designated the spindle-assembly checkpoint. However, the source of the “wait”
signal was still unclear. To this end, Rieder et. al showed that mitotic exit could
be accelerated by laser ablation of the last unattached kinetochore, providing
evidence that the “wait” signal was produced at kinetochores [84]. In the decades
following these studies, the mechanisms by which the SAC senses unattached
kinetochores and how it mediates mitotic arrest have become clearer, but many
unanswered questions remain.
For the SAC to function, the cell must first be able to detect the status of
kinetochore attachment and then respond properly. The detection function is
performed by a sensory system that monitors kinetochore-spindle attachment. In
response to unattached kinetochores, the sensory system will activate an effector
system that induces mitotic arrest via APC/C inhibition [85]. The sensory function
of the SAC begins at kinetochores, multi-subunit complexes that are the interface
between chromosomes and spindle microtubules [85]. The ‘outer’ layer contains
an intricate network of three separate complexes: The KNL1 (kinetochore
scaffold 1) complex, the MIS12 (protein MIS12 homolog) complex, and the
NDC80 (Kinetochore protein NDC80 Homolog) complex (KMN network). The
KMN network promotes spindle attachment by interaction with a calponin20

homology domain on the NDC80 complex, while the ‘inner’ layer binds to
centromeric chromatin through a histone H3 variant, CENP-A (histone H3-like
centromeric protein A) [102]. Prior to kinetochore-microtubule attachment, all
SAC proteins are recruited to kinetochores and, as spindle attachment
progresses, levels of these proteins decrease [103]. Some evidence suggests
that kinetochores serve as platforms for assembly of the SAC effector, the mitotic
checkpoint complex (MCC), but it is still not clear whether full or partial assembly
of the MCC occurs here. In either case, it is thought that the complete MCC must
be able to diffuse freely throughout the cell to inhibit the APC/C sufficiently [84,
85, 103]. Interestingly, it has been found that the SAC does not work like a
switch, but is able to be activated to different levels [104]. Furthermore, the same
study found that different microtubule-targeting agents could differentially activate
the SAC, causing gradations of APC/C inhibition and varying the extent of mitotic
delay.
Aurora Kinase B is a serine/threonine kinase that is particularly important
to SAC function [59]. During mitosis, it is found in high amounts at kinetochores
[105]. There, it phosphorylates kinetochore proteins until kinetochore-microtubule
attachment occurs, at which point its activity promptly declines. When active,
aurora kinase B phosphorylates proteins on both the inner and outer kinetochore,
including CENP-A and components of the KMN network. A key signaling function
of aurora kinase B is recruitment of MPS1 (monopolar spindle 1 kinase) to
kinetochores. MPS1, another kinase and critical SAC signaling molecule,
phosphorylates KNL1 at several MELT sequences (Met-Glu-Leu-Thr), creating
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docking sites for additional SAC proteins. These proteins include BUB1 (budding
uninhibited by benzimidazoles 1), BUB3 (budding uninhibited by benzimidazoles
3), BUBR1 (budding uninhibited by benzimidazoles 1B; BUB1B), MAD1 (mitotic
arrest-deficient 1), MAD2 (mitotic arrest-deficient 2), and CDC20, which are
either components of the MCC or promote assembly of the MCC [59, 85, 105].
The MCC is composed of three SAC proteins MAD2, BUBR1, and BUB3
in addition to CDC20. Incomplete kinetochore-microtubule attachment promotes
the assembly of this complex and its inhibition of the APC/C through formation of
APC/CCdc20-MCC complexes, while proper chromosome biorientation promotes
MCC disassembly and APC/C activation. The interplay between the mitotic
spindle, the SAC, mitotic progression and the APC/C is exceedingly complex, but
an entire class of drugs exploits these connections, providing therapy for
numerous diseases.
Importance of this study
Mitotic inhibitors are drugs that inhibit the cell cycle in mitosis. There are
several classes of antimitotics and they are used in the treatment of multiple
diseases, including viral skin infections, fungal infections, gout, and multiple
types of cancer. Classes of antimitotic drugs include the taxanes (e.g. paclitaxel,
docetaxel), vinca alkaloids (e.g. vincristine, vinblastine), colchicine,
podophyllotoxin, and griseofulvin. Importantly, these drugs all target a single
protein: tubulin. Through their interaction with tubulin, current antimitotics disrupt
microtubule dynamics through either stabilization or destabilization of
microtubules. In mitosis, the disruption of microtubule dynamics prevents proper
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attachment of kinetochores to mitotic spindle microtubules, leading to SAC
activation, APC/C inhibition, and mitotic arrest.
The taxanes are a major class of antimitotics and are commonly used to
treat lung, ovarian, and breast cancer. Despite their widespread use, there are
numerous issues concerning these drugs. As with most chemotherapeutic
agents, the taxanes induce cell death in dividing tissues, not limited to malignant
tissues. Additionally, taxanes exhibit dose-limiting neurotoxicity due to their
interference with neuronal microtubule dynamics. A major issue that continues to
receive significant attention is drug resistant cancers. Tumors frequently become
resistant to current antimitotics, including the taxanes, by mutations in tubulin or
SAC proteins. Thus, since all current antimitotics target tubulin, cancers with
these mutations are resistant to the entire class of drugs. Development of drugs
that target the regulators of mitosis, such as components of the UPS, will provide
significant benefits over the current antimitotic drugs.
There are several examples of drugs that target members of the UPS for
cancer chemotherapy, including the general proteasome inhibitor, bortezomib, for
treatment of multiple myeloma and mantle cell lymphoma. While bortezomib has
a measurable therapeutic index, it inhibits all protein degradation, which can
cause unwanted cytotoxic effects [34]. In an attempt to reduce the off-target
effects caused by overall inhibition of protein degradation, some groups have
developed small molecules to inhibit individual E3 ubiquitin ligases. One example
is Pevonedistat (MLN4924), an inhibitor of NEDD8-activating enzyme [106]. The
activity of SCF complexes requires neddylation (addition of a small, ubiquitin-like
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protein) of cullin subunits. Pevonedistat, by blocking SCF neddylation, serves as
an SCF inhibitor. Despite increased specificity over bortezomib, phase 1 clinical
trials with pevonedistat reported only modest activity [107]. Through inhibition of
all SCF ligases, pevonedistat blocks proteasomal degradation of ~20% of
proteins. Taking into account the breadth of SCF ubiquitin ligase activity, total
inhibition of SCF ligases is likely an ineffective approach. Additionally, SCF
complexes display overlapping substrate specificity due to the nature of targeting
by F-box proteins. As mentioned previously, the redundancy of F-box substratetargeting highlights the impracticality of SCF inhibition for achieving specific
therapeutic effects.
This thesis characterizes a new class of antimitotic chemotherapeutics
targeting the major regulator of cell cycle progression, the anaphase promoting
complex/cyclosome (APC/C). The strategy differs from traditional approaches, in
that core structures necessary for intermolecular interactions are targeted.
As previously mentioned, the APC/C catalytic core contains a cullin
(ANAPC2) and a zinc RING finger (ANAPC11) subunit [5]. At the inception of this
project, there were no published structures of the APC/C or its subunits.
However, crystal structures of proteins homologous to ANAPC11 and ANAPC2
were available. PDB files 1LDJ for CUL1 (ANAPC2 homologous) and RBX1
(APC11 homologous) were obtained from the protein database maintained by the
National Library of Medicine. ClustalW software was used to create alignment
files, and homology models for ANAPC2 and ANAPC11 were generated with
Modeller 9v1 [108]. ANAPC2 and ANAPC11 were joined by insightII software by
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aligning ANAPC11 to RBX1 and ANAPC2 to CUL1. Images of the generated
homology models were exported from either insightII or Chimera software.
ANAPC2:ANAPC11 homology models were then used to for in silico docking to
identify compounds predicted to bind the ANAPC11-binding region of ANAPC2
(Figure 3A). More recently, the full APC/C structure was determined by cryoelectron microscopy and added to the protein database. The homology models
were compared to the published structures for ANAPC2-CTD and
ANAPC11(protein database file 4UI9) and found to be highly similar (Figure 3B).
Two sites within the ANAPC11-binding region of ANAPC2 were screened using
SurflexDock and the ZINC drug-like library, which contained, at the time of
screening, over 3 million compounds. The results were scored and the top ~50
candidate compounds were selected for each site. A total of nine compounds,
four targeting one site and five targeting the other, were ordered for studies.
From these nine compounds, preliminary data indicate that four are cytotoxic in
various cancer cell lines. These four hit compounds include three compounds
classified as amino-2-propanols and one as a triazospiro compound (Figure 3CF). The predicted ANAPC2 binding regions for the the amino-2-propanols and
triazospiro compounds are distinct but overlapping (Figure 3A, turquoise and
green).
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Figure 3. Models of the ANAPC2:ANAPC11 binding interaction and
structures of predicted inhibitors. A) Homology models of the C-terminal
domain (CTD) of ANAPC2 (white) binding ANAPC11 (blue). Regions targeted in
silico are represented in turquoise and green. B) Published cryo-electron
microscopy structures of the binding interaction of ANAPC2-CTD (white) and
ANAPC11 (blue). The lower panels show the structures of four predicted
inhibitors: C) Compound 3; D) Compound 8; E) Compound 10; F) Compound 11.
Structures in panel A courtesy of B.F. Taylor and J.O. Trent. Panel B structures
from PDB file 4UI9.
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Based on the role of the APC/C in cell cycle regulation, the overarching
hypothesis is that compounds predicted to inhibit the APC/C will induce mitotic
arrest and cell death in malignant cells. In this thesis, the following are
demonstrated: 1) Hit compounds are cytotoxic in multiple cancer types, including
lung, ovarian, pancreatic, and melanoma cancers; 2) Hit compounds induce cell
cycle mitotic or G1-arrest depending on the functionality of the SAC; 3) Hit
compounds induce apoptosis selectively in malignant cells. This thesis, and
future work, will provide the groundwork for development of these compounds
into a novel class of antimitotic chemotherapeutics, which are critically needed
for treatment of anti-microtubule-resistant tumors. Additionally, these compounds
will serve as useful tools for studying the mechanisms of mitosis and the APC/C.

27

METHODS AND MATERIALS
CELL CULTURE
Cells were cultured at 37°C with 5% CO2 in a humidified incubator. A549
and A375 cells were cultured in Dulbecco’s Modified Eagle’s Medium (Hyclone,
Logan, UT) supplemented with 10% fetal bovine serum (Hyclone), 100 U/mL
penicillin and 10 U/mL streptomycin. A2780/CP70 and H460 cells were cultured
in RPMI-1640 (Hyclone) supplemented with 10% fetal bovine serum (Hyclone),
100 U/mL penicillin and 10 U/mL streptomycin. SKOV-3 cells were cultured in
McCoy’s 5A (Hyclone) supplemented with 10% fetal bovine serum (Hyclone),
100 U/mL penicillin and 10 U/mL streptomycin. Telomerase-immortalized diploid
fibroblasts, tGM24 cells, were cultured in Eagle’s MEM containing Earle’s salts
(GIBCO-BRL) supplemented with 0.1 mM non-essential amino acids, 2 mM Lglutamine 10% fetal bovine serum (Hyclone), 100 U/mL penicillin and 10 U/mL
streptomycin. SK-Mel-28 cells were cultured in α-MEM (Hyclone) supplemented
with 10% fetal bovine serum (Hyclone), 100 U/mL penicillin and 10 U/mL
streptomycin. HBEC3-KT cells were cultured in Keratinocyte-SFM (GIBCO)
supplemented with 50 µg/mL bovine pituitary extract, 5 ng/mL recombinant
human EGF, and 100 U/mL penicillin and 10 U/mL streptomycin.
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ALAMARBLUE ASSAYS
Cells were seeded in 96-well plates at 8000 cells/ well (A549, H460) or
2000 cells/ well (HBEC3-KT) and allowed to attach overnight. Cells were treated
with seven concentrations of compounds 3 (5-60 µM), 8 (10-100 µM), 10 (5-60
µM), or 11 (1-20 µM). DMSO (0.1%), paclitaxel (100 nM), and staurosporine (10
µM) were used as controls. Concentration ranges and treatment times for lead
compounds were chosen based on prior photomicroscopy studies of cell
morphology and cell death. Cells were incubated with compounds for 48 h, at
which point alamarBlue (Bio-Rad, Hercules, CA) was added to each well to 10%
total volume. Plates were incubated with alamarBlue for 4 h at 37°C and 5%
CO2. The fluorescence of each well was measured with an excitation wavelength
of 530 nm and an emission wavelength of 590 nm.
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COLONY FORMING ASSAYS
Cells were plated in triplicate 6-well plates at a 100 cells/well (3 wells) or
500 cells/well (3 wells) and allowed to attach overnight. Cells were then exposed
to DMSO or compounds at the indicated concentrations dissolved in DMSO (final
[DMSO] = 0.1%). The time of incubation with compounds varied from 5 to 14
days between cell lines due to differences in doubling times. Generally, colonies
become visible when clusters reach 32 cells or more, so ≥5 doublings are
required to fit the definition of a colony. Following incubation with compounds,
colonies were fixed and stained with crystal violet. Stained colonies were counted
and the colony forming efficiency (CFE) was calculated by dividing the number of
colonies formed by the number of cells plated. These values are then used to
calculate the colony forming efficiency relative to the DMSO control by the
following formula:
Colonies (% control) =

Compound CFE
*100
DMSO CFE
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MITOTIC INDEX ANALYSIS
Cells were seeded in 6-well plates at 1.5 x 105 cells/ well. After allowing
cells to attach for 24 h, DMSO, paclitaxel (100 nM), or compounds 3, 8, 10, and
11 were added directly to the media. Concentration ranges and treatment times
for lead compounds were chosen based on prior photomicroscopy studies of cell
morphology and cell death. After 24 h cells were harvested for mitotic index
determination by trypsinization and combined with media and wash. Cells were
collected by centrifugation and pellets were resuspended and swollen in 2.5 mL
hypotonic solution (0.075 M KCl). The suspension was incubated at room
temperature for 15 min. Next, 0.25 mL fixative solution (3:1 methanol: acetic
acid) was added, and cells were pelleted by centrifugation. Pellets were
resuspended in 2.5 mL fixative solution and incubated at room temperature for at
least 20 min. Cells were pelleted again and resuspended in 2.5 mL fresh fixative
solution. Aliquots were then dropped onto glass slides, air dried, and stained with
Wright Giemsa solution. Slides were examined under a microscope for
determination of mitotic index, mitotic catastrophe, and apoptosis. A minimum of
three slides per treatment were prepared and 200 cells were counted per slide.

31

G1/S SYNCHRONIZATION
Cells were synchronized at G1/S by double thymidine block. Experiments
were performed with 5 X 105 cells in 6 cm dishes. Cells were plated and allowed
to attach overnight, followed by incubation with 2 mM thymidine for 20 h.
Thymidine was removed to allow cells to re-enter the cell cycle by aspirating
media, washing twice with PBS, and adding fresh media. After 8 h, cells were
treated with 2 mM thymidine for 16 h. Cells were then allowed to re-enter the cell
cycle by removing media, washing twice with PBS, and adding fresh media.
DMSO (0.1%), compounds 3 (10 µM), 8 (40 µM), 10 (10 µM), and 11 (5 µM), or
nocodazole (100 nM) were added directly to the media 5 h after release from
G1/S block. Total cellular lysates were prepared every hour for the next 7 h.
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WESTERN BLOTTING
Cells were lysed with lysis solution (10 mM Tris-HCl pH 7.4, 1 mM EDTA,
0.1% sodium dodecyl sulfate, 1 mM phenylmethylsulphonylfluoride, 1 mM
Na3VO4, and 1X cOmpleteTM Protease Inhibitor Cocktail (Roche, #04693116001,
Basel, Switzerland)). Lysates were sonicated twice for 2-3 s on ice and
centrifuged at 13,000 x g for 15 min at 4ºC to remove debris. Total protein
concentration in supernatant was determined by BCA assay (Pierce, #23225,
Waltham, MA) using bovine serum albumin as standard. Proteins were loaded
(20-30 µg/lane) and resolved by sodium dodecylsulfate-polyacrylamide gel
electrophoresis in 12% Mini-PROTEAN® TGX™ Precast Protein Gels (Bio-Rad,
#4561046, Hercules, CA). Proteins were transferred to nitrocellulose
membranes, which were stained with Ponceau S (Sigma, St. Louis, MO) to check
for equal protein loading and transfer. Membranes were blocked in 5% milk in
TBST (10 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.1% Tween-20) for 2 h at room
temperature. Membranes were probed with mouse monoclonal antibodies for ßactin (Sigma, St. Louis, MO, # A5441, 1:10,000 dilution) and cyclin B (BD
Transduction Laboratories, Franklin Lakes, NJ, #610219, 1:500 dilution) or rabbit
monoclonal antibodies for securin (Cell Signaling Technology, Danvers, MA,
#13445, 1:1000 dilution) and vinculin (Cell Signaling Technology, #13901, 1:1000
dilution). Secondary antibodies (Cell Signaling Technology, Danvers, MA, antimouse IgG, #7076, 1:3000 dilution or anti-rabbit, #7074, 1:2000 dilution)
conjugated to horseradish peroxidase were bound to primary antibodies and
protein bands for ß-actin, cyclin B, securin, and vinculin were detected using
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enhanced chemiluminescence (ECL) Plus Western Blotting Substrate (Pierce,
#32123, Waltham, MA). Bands were developed using a ChemiDoc XRS System
(Bio-Rad, #1708265, Hercules, CA). ß-actin and vinculin served as the loading
control.
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FLOW CYTOMETRY
Cells were harvested by trypsinization and fixed in 1 mL of ice-cold 70%
ethanol overnight at 4°C. Following fixation, cells were centrifuged at 1,500 x g
and cell pellets were resuspended in 500 µL PBS containing 10 µg/mL propidium
iodide and 100 U/mL RNase A (Sigma) for 30 min at room temperature. Stained
cells were analyzed on a FACSCalibur (Becton Dickinson, San Jose CA) using
doublet discrimination. Propidium iodide fluorescence was collected on FL2
(585/42 nm) using linear amplification, and at least 20,000 events/ sample were
analyzed. CellQuest software (Beckton Dickinson) was used for data collection
and Modfit software (Verity Software House, inc., Topsham ME) was used for
analysis of cell cycle distribution.
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APOPTOSIS ASSAYS
Apoptosis was measured using the Apo-ONE® Homogeneous Caspase3/7 Assay from Promega. This assay utilizes a pro-fluorescent caspase-3/7
substrate that is converted to a highly fluorescent molecule upon cleavage by
caspase-3/7. Caspase-3/7 activity, and therefore apoptosis, is directly correlated
to the amount of fluorescence detected. Cells were grown at either 7500 cells/
well (A2780/CP70) or 3000 cells/ well (SKOV-3, tGM24) in 96-well plates in 100
µL media for 24 h. A549, H460, and HBEC3-KT cells were treated with DMSO
(0.1%), compounds 3 (5-60 µM), 8 (10-80 µM), 10 (1-25 µM), and 11 (1-15 µM).
A2780/CP70 cells were treated with DMSO (0.1%), compounds 8 (20-80 µM), 10
(1-20 µM), and 11 (1-20 µM), or paclitaxel (100 nM). SKOV-3 and tGM24 cells
were treated with DMSO (0.1%), compounds 8 (10-60 µM), 10 (1-10 µM), and 11
(1-10 µM), or paclitaxel (100 nM). Cells were incubated for 24 h (A2780/CP70,
SKOV-3), 36 h (A549, H460, HBEC3-KT), or 48 h (tGM24). Concentration ranges
and treatment times for lead compounds were chosen based on prior
photomicroscopy studies for induction of apoptosis. Cells were exposed to ApoONE® Caspase-3/7 Reagent (Promega, Madison, WI) by adding 100 µL to each
well. Contents of the wells were gently mixed using a plate shaker at 300-500
rpm, and cells were incubated for an additional 1 h, prior to fluorescence
measurement. The fluorescence of each well was then measured using 499 nm
excitation and 521 emission wavelengths.
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RESULTS

ALAMARBLUE SCREENING IN MULTIPLE CELL TYPES
The purpose of this part of the study was to perform initial screening of
candidate compounds for cytotoxic properties. Compounds were initially
screened by alamarBlue assays. These assays are similar to tetrazolium dyebased MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays
in that they both utilize reporter dyes to measure the reductive capacity, and,
therefore, the metabolic activity, of the cell. Additionally, both assays allow rapid
screening of multiple compounds. AlamarBlue differs in that it can be added
directly to the cell culture media, unlike MTT, which requires washing steps.
Inhibition of the APC/C is predicted to cause mitotic arrest, so the wash steps
with MTT assays may result in the loss of these loosely-attached cells. Thus,
alamarBlue was used because it allows for the measurement of cells in any cell
cycle phase. Several predicted APC/C inhibitors (3, 10, and 11) were found to
reduce viability effectively in multiple cell lines representing malignant and nonmalignant lung tissues (Figure 4). While these assays indicate that compounds
have no therapeutic window, further investigations are necessary to determine if
compounds induce cell death or simply prevent cell division (cytostasis).
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Figure 4. Hit compounds reduce viability in lung cell lines. AlamarBlue
assays were performed with compounds 3, 8, 10, and 11 in A549 and H460,
malignant lung cell lines, and HBEC3-KT, non-malignant lung cells. Cells were
exposed to compounds 3, 8, 10, and 11 at the indicated concentrations for 48 h.
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COLONY FORMING ASSAYS IN MULTIPLE CELL TYPES
AlamarBlue assays don’t distinguish between cytostasis and reduced
viability. While alamarBlue assays are a useful tool for screening, they are not a
true measure of inhibition of replicative ability. To confirm the results of the
alamarBlue viability date, colony forming assays, which provide a direct measure
of the effect compounds have on replicative capacity, were performed. The
results of colony forming assays were consistent with the alamarBlue data,
indicating that compounds 3, 8, 10, and 11 dose-dependently reduce colony
formation (Figure 5). Compounds effectively reduced colony formation in cell
lines representing malignant lung, ovarian, pancreatic, and melanoma tissues.
Compounds also reduced colony formation in HBEC3-KT, non-malignant lung
cells, and tGM24, telomerase-immortalized diploid fibroblasts. These nonmalignant cells, however, were found to be alive and attached to the plate, but
had not divided to form colonies (Figure 6). The observation that compounds are
cytotoxic to malignant cells, but cytostatic in non-malignant cells provides
evidence for a therapeutic window. Interestingly, when compared to DMSOtreated cells, HBEC3-KT cells exposed to hit compounds appear much smaller,
suggesting that compounds interfere with pathways regulating cell growth and
metabolism. Therefore, it will be necessary to investigate these pathways as
sources of off-target effects, in the future.
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Figure 5. Hit compounds reduce colony forming ability of multiple lung,
ovarian, pancreatic, and melanoma cell lines. Colony forming assays
performed in lung (top row), ovarian and fibroblasts (second row), pancreatic
(third row), and melanoma (fourth row) cell lines. Lung cell lines (A549, H460,
HBEC3-KT) were treated with compounds 3, 8, 10, and 11 at the indicated
concentrations. Ovarian cell lines (A2780/CP70, SKOV-3) and fibroblasts
(tGM24) were treated with compounds 8, 10, and 11 at the indicated
concentrations (data courtesy of Doug Saforo). Pancreatic (MIAPACA2, PANC1,
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S2VP10) and melanoma (SK-MEL-28, A375) cell lines were treated with
compounds 3, 8, 10, and 11 (data courtesy of Brian Sils).

Figure 6. Compounds cause cytostasis in non-malignant lung cells. Phase
contrast photomicrographs of HBEC3-KT cells stained with crystal violet following
exposure to A) compound 3 (20 µM), B) compound 8 (20 µM), C) compound 10
(20 µM), D) compound 11 (2 µM), or E) DMSO. All photos were taken at 10X
magnification.
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MITOTIC INDEX ANALYSIS OF MULTIPLE CELL TYPES
The cytotoxicity of several hit compounds has been demonstrated, but it is
possible that this toxicity could be due to off target effects. These compounds are
predicted to inhibit the APC/C, which is essential for mitotic progression,
particularly the metaphase-anaphase transition. Thus, an increase in the mitotic
index in cells exposed to these compounds would be consistent with APC/C
inhibition. Therefore, mitotic index analyses were performed to determine the
effect of compounds. The results of these experiments indicate that compounds
3, 8, 10, and 11 significantly increase mitotic index compared to DMSO controls
(Figure 7). Compounds increased mitotic index in multiple cell types, including
malignant and non-malignant lung and ovarian cells (Figure 7). However, these
results and the results of colony forming assays indicate that non-malignant cells
are able to survive mitotic arrest induced by these compounds, while malignant
cells undergo cell death.
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Figure 7. Lung, ovarian, and fibroblast cells exposed to hit compounds
have increased populations in mitosis. Mitotic indices determined in lung (AC), ovarian (D, E) and telomerase-immortalized diploid skin fibroblasts (F). Lung
cell lines A549 (A), H460 (B), and HBEC3-KT (C) were treated with Taxol (100
nM) and compounds 3 (10 µM), 8 (60 µM), 10 (10 µM), and 11 (5 µM).
Treatments for A2780/CP70 (D) were Taxol (10 nM) and compounds 8 (5 µM),
10 (0.4 µM), and 11 (0.4 µM). SKOV-3 (E) were treated with Taxol (50 nM) and
compounds 8 (20 µM), 10 (1 µM), and 11 (1 µM). tGM24 (F) cells were treated
with Taxol (50 nM) and compounds 8 (20 µM), 10 (1 µM), and 11 (1 µM). Percent
difference in mitoses was analyzed by one-way ANOVA (✱, P<0.05; ✱✱,
P<0.01)
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STABILITY OF APC/C SUBSTRATES IN SYNCHRONIZED A375 CELLS
The APC/C is essential for mitotic progression, particularly the
metaphase-anaphase transition. Non-functional APC/C will be unable to target its
substrates for ubiquitinylation and degradation. These substrates include cyclin
B, whose degradation is required for mitotic exit, and securin, which must be
degraded to allow anaphase progression. As a counterpoint, inhibition of the
APC/C does not necessarily result in stabilization of its substrates. For example,
proteolysis of APC/C(CDC20) substrate cyclin A was not delayed in the presence
of active SAC in vitro [109]. Additionally, NEK2A (never in mitosis gene a-related
kinase 2), has been shown to be targeted by APC/C(CDC20) independent of
SAC activation [110]. Furthermore, some cancers with weakened checkpoints
may undergo “mitotic slippage,” whereby cells slowly degrade cyclin B and
prematurely exit mitosis due to incomplete APC/C inhibition [111, 112]. While
there is no evidence suggesting that cyclin B or securin can be degraded when
the APC/C is completely inhibited, these studies highlight the complex nature of
APC/C regulation and activity. Inhibition of the APC/C is most likely to cause cell
cycle arrest in mitosis. However, the APC/C also contributes to progression
through G1-phase of the cell cycle [2, 27]. Thus, it is possible that APC/C
inhibition may result in G1-arrest, or both G1- and mitotic-arrest.
To provide further evidence that hit compounds target the APC/C and
characterize the mechanism of cell cycle arrest, the kinetics of cyclin B and
securin degradation in synchronized A375 cells were analyzed. Synchronization
of cultures was performed because it is possible that hit compounds targeting the
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APC/C may not inhibit the total APC/C population. Incomplete inhibition of the
APC/C would allow slow degradation of its target proteins, resulting in mitotic
delay, similar to mitotic slippage by weakened checkpoints, not mitotic arrest.
While mitotic progression may be slowed, the population of mitotic cells is likely
to be low at any certain time. Therefore, if hit compounds do not completely
inhibit APC/C activity, their effects may be masked in asynchronous cultures. To
increase the likelihood of obtaining highly synchronous cultures, A375 cells were
chosen, because they have a short doubling time. Following G1/S blockade,
synchronized cells were allowed to re-enter the cell cycle for 5 h before adding
compounds. After addition of compounds, APC/C targets, securin and cyclin B,
were measured every hour for 7 h by western blot (Figure 8). In DMSO-treated
cells, cyclin B and securin levels steadily increase from 6-9 h after release,
followed by a sharp decline from 10-12 h, indicating that these cells are exiting
mitosis between 9 and 10 h after G1/S. Nocodazole is commonly used to arrest
cells in mitosis during prometaphase. Consistent with mitotic arrest, the levels of
cyclin B and securin in nocodazole-treated cells remained elevated through 12 h
after G1/S, our final timepoint. Compounds 3, 8, 10, and 11 had variable effects
on cyclin B and securin levels. Similar to nocodazole, compound 3 completely
stabilized cyclin B and delayed securin degradation until 12 h after G1/S,
consistent with APC/C inhibition and mitotic arrest. Conversely, compound 8 had
no effect on cyclin B levels, when compared to DMSO, but securin was
stabilized. Cells treated with compounds 10 and 11 displayed delayed kinetics of
degradation for both cyclin B and securin. In these cells, cyclin B and securin
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levels began to decline after 9 h, but the rate of decline was slowed in
comparison to DMSO. These delayed kinetics of degradation suggest
compounds 10 and 11 cause partial inhibition of the APC/C, leading to mitotic
delay, not mitotic arrest.
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Figure 8. APC/C mitotic targets display extended kinetics of degradation
when exposed to hit compounds. Western blot time course analysis of cyclin B
and securin in synchronized A375 cells treated with compounds 3 (10 µM), 8 (40
µM), 10 (10 µM), and 11 (4 µM). DMSO and nocodazole (100 nM) were used as
controls. Vinculin was detected to ensure equal protein.
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CELL CYCLE EFFECTS OF HIT COMPOUNDS IN A SAC-DEFICIENT
MELANOMA CELL LINE
As detailed previously, resistance to microtubule-targeting
chemotherapeutics is a major issue. Many cases of resistance result from
mutations in SAC proteins [113]. These mutations lead to SAC-deficient cancers,
which are not arrested in mitosis in response to disruption of microtubule
dynamics. Recent studies have focused on the development of drugs targeting
the proteins that regulate the mitotic spindle, including the motor protein Kinesin5, Aurora kinases, and Polo-like kinases. While these drugs are less neurotoxic
than taxanes, their efficacy is no better or worse against solid tumors [111].
Targeting the master regulator of mitosis, the APC/C, addresses these issues.
The APC/C is essential to cell proliferation and mutations causing dysfunctional
APC/C result in non-viable cells [99, 114]. Therefore, unlike SAC inactivation,
which promotes resistance, APC/C inactivating mutations should be fatal. In
SAC-proficient cells, unattached kinetochores cause mitotic arrest through SAC
activation, but the downstream target of the SAC is the APC/C. Therefore, SACdeficient cells should arrest in mitosis in response to APC/C inhibition because
compounds targeting the APC/C bypass the need for a functional SAC.
To examine the effects of hit compounds in SAC-deficient cells, several
experiments were performed in SK-MEL-28 cells, which are resistant to
paclitaxel-induced mitotic arrest (Figure 9). To examine cytotoxicity of hit
compounds in this cell line, colony forming assays were performed with
compounds 8, 3, and 3a1 (an analog of 3) (Figure 9A). All three compounds
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Figure 9. Compounds targeting distinct, overlapping regions of ANAPC2
induce cell cycle arrest at different points in SAC-deficient melanoma cells.
A) Colony forming assays with SK-MEL-28 cells exposed to the indicated
concentrations of compounds 3, 3a1, and 8. B) Quantitation of mitoses, mitotic
catastrophes, and apoptosis by 20 µM compounds 3, 3a1, and 8. C) Histograms
from flow cytometry of propidium iodide-stained cells exposed to 20 µM
compounds 3, 3a1, and 8 for 24 h. D) Quantitation of data in panel C (# = p<0.05
vs. DMSO). Data courtesy of Brian Sils and Shuchismita Satpathy.
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dose-dependently reduced colony formation. Mitotic index analysis revealed that
compounds 3 and 3a1 increased the population of mitotic cells, but the mitotic
index of cells treated with compound 8 was not changed (Figure 9B). Cell cycle
analysis by propidium iodide staining and flow cytometry indicate that
compounds 3 and 3a1 increased the population of cells in the G2/M
compartment and decreased the population in G1/S, correspondingly (Figure 9C,
top right panel, lower left panel). Interestingly, exposing cells to compound 8 had
the opposite effect, with an increase in the G1/S compartment and a
corresponding decrease in the G2/M (Figure 9C, lower right panel). The cause of
this difference in cell cycle distribution induced by compounds 3 and 3a1 vs.
compound 8 is unclear, at this time.
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APOPTOSIS ASSAYS IN LUNG AND OVARIAN CELL LINES
Hit compounds induced mitotic arrest and cell death in multiple cancer cell
types. The mechanism of cell death is unclear, but the prediction is that
compounds induce apoptosis in cancer cells. To investigate the mechanism of
cell death induced by hit compounds, apoptosis assays were performed to detect
active caspase-3/7, a common marker of apoptosis. Malignant lung cells treated
with compounds 3, 8, 10 & 11 and ovarian cell lines treated with compounds 8,
10 &11 displayed increased activation of apoptosis (Figure 10A, B, D, E). In
contrast, non-malignant HBEC3-KT lung cells and tGM24 diploid skin fibroblast
cells, showed no increase in caspase-3/7 activity, and, therefore, no apoptosis
activation, when exposed to compounds 3, 8, 10 & 11 (Figure 10C, F). This result
is consistent with the cytostatic effect of compounds in non-malignant cells
observed in colony forming assays.
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Figure 10. Levels of active caspase-3/7 are elevated in lung and ovarian
cancer cells following exposure to hit compounds. Apoptosis assays were
performed with compounds 8, 10, and 11 in SKOV-3 and A2780/CP70 ovarian
cancer cells, and tGM24 telomerase-immortalized fibroblasts. Ovarian cells were
exposed to compounds 8, 10, and 11 for 24 h at the indicated concentrations
before caspase-3/7 activity was measured. Fibroblast cells were exposed to
compounds 8, 10, and 11 for 48 h at the indicated concentrations before
caspase-3/7 activity was measured.
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DISCUSSION
Mitotic inhibitors are critical tools in the treatment of cancer. Recently,
however, numerous issues concerning current microtubule-targeting antimitotics,
have received increased attention. Arguably the most significant issue with antimicrotubule drugs is the development of resistant tumors through mutations in
SAC proteins. Currently, the only approved antimitotic agents target tubulin,
meaning that resistant tumors are resistant to all antimitotic drugs. The work
described in this thesis is significant because it provides evidence that targeting
the proteins that regulate mitotic progression, namely the APC/C, is a strategy
with numerous potential benefits over microtubule-targeting drugs. Chief among
these benefits is the fact that targeting the APC/C bypasses the need for a
functional SAC, meaning that compounds inhibiting the APC/C should be
effective in tumors resistant to current antimitotics. The APC/C is crucial for the
metaphase-anaphase transition, but also plays significant roles in mitotic exit and
G1 progression. The fact that the APC/C regulates multiple points in the cell
cycle should increase the likelihood that APC/C inhibition will cause cell cycle
arrest. This hypothesis is supported by results of studies with paclitaxel-resistant
melanoma cells (Figure 9). Taken together, the data reported in this thesis
provide evidence that further research and development of compounds targeting
the APC/C will lead to a valuable new class of antimitotic agents for cancer
treatment and for research into APC/C function.
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AlamarBlue, combined with colony forming data, demonstrates that hit
compounds reduce the replicative ability of multiple cancer types, including lung,
ovarian, pancreatic, and melanoma. This finding is consistent with the prediction
that compounds inhibit the APC/C, leading to mitotic arrest and cell death. The
same assays performed in SAC-deficient cells showed that the APC/C is a
suitable target for the treatment of paclitaxel-resistant cancers. There was a
general trend in the effective concentrations of these compounds, with compound
11 killing cells at the lowest concentrations, followed sequentially by compounds
10, 3, and 8. However, compounds 3, 8, and 10 have a broader therapeutic
window, as evidenced by colony forming assays and apoptosis assays,
suggesting further development will allow improved efficacies and selectivity.
Mitotic index analysis of hit compounds in the same cell lines revealed
significant increases in the population of mitotic cells, compared to DMSO.
Generally, mitotic index was much greater in cells treated with paclitaxel than
with hit compounds. However, direct comparisons between the efficacy of hit
compounds and paclitaxel are not useful, at this early stage of development.
These hit compounds contain several structural features that will allow the
synthesis of analog libraries for structure-activity relationship studies (SAR) to
improve efficacy.
This work also demonstrates that, to varying degrees, candidate
compounds stabilize or delay the degradation of two APC/C substrates that are
key to mitotic progression: cyclin B and securin. Interestingly, exposure to either
compound 3 or compound 8 resulted in the opposite pattern of cyclin B and
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securin stabilization. Compound 3 completely stabilized cyclin B and delayed
securin degradation, consistent with mitotic arrest and APC/C inhibition.
Compound 8 had no effect on cyclin B, but appeared to slow the kinetics of
securin degradation. Degradation of securin is required for activation of separase
and cleavage of cohesins, so this result suggests that cells treated with
compound 8 may be exiting mitosis into a pseudo-G1 state, in which cells contain
2C DNA content. Several studies have demonstrated other mechanisms by
which securin levels can be reduced, indicating that total APC/C inhibition may
not result in full stabilization. Extended mitotic arrest can lead to mitotic
catastrophe, a type of mitosis-linked cell death in response to chromosomal
damage, and some have found that DNA damage can cause decreased
expression of securin via TP53-mediated repression [115]. Therefore, if
compounds cause extended mitotic arrest and mitotic catastrophe, as observed
in ovarian cancer cells shown in Figure 6, total stabilization of securin may not
occur. Additionally, UV radiation can cause mitotic arrest and catastrophe, and
was found to lead to degradation of securin mediated by an SCF complex
(SKP1-CUL1-βTrCP) [54]. The phosphorylated, mitotic form of securin has also
been found to be a target for SCF-mediated degradation [55]. These redundant
mechanisms for the degradation of securin may account for some of the
differences seen in its pattern of degradation. Further complicating matters, the
APC/C and SCF complexes are highly similar and the homology models were
generated using published structures of the SCF. Therefore, it is possible that
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compounds may be targeting one or the other or both complexes, a factor that
complicates interpretations of these data.
Importantly, candidate compounds were determined to be effective in
SAC-deficient, paclitaxel-resistant SK-MEL-28 cells. These cells, interestingly,
were arrested at different cell cycle stages when exposed to either compound 3
or compound 8. The mechanism to account for this difference is still unclear.
However, one possibility is differences in the predicted ANAPC2 binding
interactions between the two (Figure 11).
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Figure 11. Two regions of ANAPC2 targeted in silico and predicted binding
interactions of compounds 3 and 8. A) Homology models of the C-terminal
domain of ANAPC2 (white) and ANAPC11 (blue) showing two regions of the
ANAPC11-binding domain of ANAPC2 that were targeted in silico (turquoise,
green). B) Predicted binding interaction of compound 3 with ANAPC2 (white) in
its ANAPC11 (blue) binding domain. C) Predicted binding interaction of
compound 8 with ANAPC2 (white) in its ANAPC11 (blue) binding domain. D)
Overlay of the predicted binding interactions of compounds 3 (red) and 8
(turquoise) with ANAPC2 (white).
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Compound 3 is a triazospiro-containing compound, while compound 8 contains
an amino-2-propanol structure. The two compounds are predicted to target
distinct but overlapping sites at the ANAPC11-binding region of ANAPC2 (Figure
11B-D). It is possible that one or both compounds, rather than preventing binding
of ANAPC11, alter the binding interaction. Changing the binding interaction could
lead to altered, rather than inhibited, activity of the APC/C, increasing or
decreasing its ability to ubiquitinylate certain substrates, leading to arrest in either
mitosis or G1, depending on the effect. As mentioned previously, we cannot yet
rule out the possibility that compounds inhibit SCF complexes and not the
APC/C. Therefore, it is possible that these two compounds interact differently
with these two E3s, leading to the observed differences in cell cycle distribution.
The activity of these compounds in SAC-deficient cells is an exciting
finding, as it suggests further development may result in a class of drugs that can
be used in tumors resistant to tubulin-targeting drugs.
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FUTURE STUDIES
A major issue concerning the future of this project is demonstration that
compounds are specifically targeting the APC/C. While much of the data are
consistent with APC/C inhibition, there are other explanations for the effects of
these compounds, such as interactions with the CUL1 and RBX1 subunits of
SCF complexes. Future studies will be required to demonstrate the specificity of
these compounds for the APC/C. Direct binding of compounds to ANAPC2 could
be demonstrated using recombinant ANAPC2 and ANAPC11 for in vitro binding
reactions with hit compounds. However, inhibition of ANAPC2:ANAPC11
complex formation could also be demonstrated in cells treated with compounds
by immunoprecipitation of one or the other, followed by western blots to detect
the presence of its binding partner. In addition to showing that compounds
prevent ANAPC2:ANAPC11 binding, it is also necessary to demonstrate that
they inhibit the catalytic activity. APC/C inhibition should result in decreased
ubiquitinylation of its substrates. However, previous work has shown, however,
that only ANAPC11, not ANAPC2, is required for ubiquitinylation of cyclin B
[108]. Others have shown that ubiquitinylation of cyclin B can be catalyzed in the
presence of Zn2+ and an E2 enzyme [23]. Thus, preventing the association of
rAPC11 with rAPC2 is not expected to totally abrogate cyclin B ubiquitinylation.
To demonstrate inhibition of securin ubiquitinylation in vitro, reactions can be
performed using recombinant ANAPC2, ANAPC11, UBE2C, and an E1 enzyme.
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Like the binding reactions, inhibition of ubiquitinylation can also be shown with
cells in culture by immunoprecipitating securin, following exposure to
compounds.
This study provides evidence for compound-induced stabilization of
APC/C mitotic substrates in one melanoma cell line. Future work will involve
further characterization of the effects on APC/C substrates in other cancer types,
such as the lung, ovarian, and pancreatic cells used in this study. In addition to
analysis in other cell lines, future studies will examine how compounds affect the
stability of APC/C targets in G1, such as geminin, FOXM1, and CDH1. These G1
target proteins are likely stabilized in SAC-deficient cells, such as SK-MEL-28
melanoma cells.
Further work using SAC-deficient cancers is also necessary if compounds
are to be demonstrated as a viable alternative to microtubule-targeting drugs. In
addition to cell lines which have developed resistance to these drugs by natural
means, compounds will be tested in cells that have the SAC knocked-down by
siRNA.
Additionally, developing these compounds into drug-like molecules will
require further SAR studies. Finally, In vivo animal studies will be necessary to
demonstrate that these compounds may be useful for the treatment of human
cancers.
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APPENDIX
LIST OF ABBREVIATIONS
ANAPC1

Anaphase Promoting Complex Subunit 1

ANAPC10

Anaphase Promoting Complex Subunit 10

ANAPC11

Anaphase Promoting Complex Subunit 11

ANAPC2

Anaphase Promoting Complex Subunit 2

ANAPC2CTD

Anaphase Promoting Complex Subunit 2 C-terminal
Domain

ANAPC3

Anaphase Promoting Complex Subunit 3

ANAPC4

Anaphase Promoting Complex Subunit 4

ANAPC5

Anaphase Promoting Complex Subunit 5

ANAPC6

Anaphase Promoting Complex Subunit 6

ANAPC8

Anaphase Promoting Complex Subunit 8

ANOVA

Analysis of Variance

APC/C

Anaphase Promoting Complex/ Cyclosome

ATP

Adenosine Triphosphate

BCA

Bicinchoninic Acid

Bora

Protein Aurora Borealis

BRCA1

Breast Cancer Type 1 Susceptibility Protein

BUB3

Budding Uninhibited by Benzimidazoles 3
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BUBR1

Budding Uninhibited by Benzimidazoles 1: BUB1B

CDC20

Cell Division Cycle 20

CDC25A

Cell Division Cycle 25A

CDH1

CDC20 Homolog 1

CDK

Cyclin-dependent Kinase

CDK1

Cyclin-dependent Kinase 1

CDKN

Cyclin-dependent Kinase Inhibitor

CDKN1A

Cyclin-dependent Kinase Inhibitor 1A

CDKN1B

Cyclin-dependent Kinase Inhibitor 1B

CDKN1C

Cyclin-dependent Kinase Inhibitor 1C

CDT1

Chromatin Licensing and DNA Replication Factor 1

CDT2

Chromatin Licensing and DNA Replication Factor 2

CENP-A

Histone H3-like Centromeric Protein A

CFE

Colony Forming Efficiency

CHK1

Checkpoint Kinase-1

CRL

Cullin-RING Ligase

C-terminus

Carboxy-terminus

CUL1

Cullin-1

DMSO

Dimethyl Sulfoxide

DNA

Deoxyribonucleic Acid

DUB

Deubiquitinating Enzyme

E1

Ubiquitin-activating Enzyme

E2

Ubiquitin-conjugating Enzyme

E3

Ubiquitin Ligase
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ECL

Enhanced Chemiluminescence

EDTA

Ethylenediaminetetraacetic Acid

EGF

Epidermal Growth Factor

EMI1

Early Mitotic Inhibitor 1

FBXL

F-box/ LRR-repeat Protein

FBXL1

F-box/ LRR-repeat Protein 1

FBXO

F-box Only Protein

FBXO1

F-box Only Protein 1

FBXO5

F-box Only Protein 5

FBXW

F-box/ WD Repeat-containing protein

FBXW1

F-box/ WD Repeat-containing protein 1

FBXW7

F-box/ WD Repeat-containing protein 7

FOXM1

Forkhead Box Protein M1

G1

Gap 1

G2

Gap 2

HECT

Homologous to E6-AP C-terminus

KIFC1

Kinesin Family Member C1

KMN
Network

KNL1-MIS12-NDC80 Network

KNL1

Kinetochore Scaffold 1

LRR

Leucine-rich Repeats

M

Mitosis

MAD1

Mitotic Arrest-deficient 1

MAD2

Mitotic Arrest-deficient 2

MCC

Mitotic Checkpoint Complex
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MDM2

Mouse Double Minute 2

MELT

Met-Glu-Leu-Thr

MPS1

Monopolar Spindle 1 Kinase

MTT

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide

NEDD8

Neural Precursor Cell Expressed Developmentally Down
regulated Protein 8

NEK2A

Never in Mitosis Gene A-related Kinase 2

N-terminus

Amino-terminus

PBS

Phosphate-buffered Saline

PDB

Protein Database

PHD

Plant Homeodomain

PLK1

Polo-like Kinase 1

PLK4

Polo-like Kinase 4

pre-RC

Pre-replication Complex

PTM

Post-translational Modifications

RAD21

Double-strand-break Repair Protein rad21 Homolog

RBX1

RING-box Protein 1

RING

Really Interesting New Gene

RNA

Ribonucleic Acid

S

Synthesis, DNA Replication

SAC

Spindle Assembly Checkpoint

SAR

Structure Activity Relationship

SCF

SKP/Cullin/F-box-containing Complexes

siRNA

Small Interfering RNA
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SKP1

S-phase Kinase-associated Protein 1

SKP2

S-phase Kinase-associated Protein 2

TBST

Tris-buffered Saline with Tween ® 20

TP53

Tumor Protein P53

TPR

Tetratricopeptide Repeat

UBE2C

Ubiquitin-conjugating Enzyme E2 C

UPS

Ubiquitin-proteasome System

USP37

Ubiquitin Carboxyl-terminal Hydrolase 37

UV

Ultraviolet

WEE1

Wee1-like Protein Kinase

Zn

Zinc

β-TrCP

Beta-transducin Repeat Containing Protein
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